Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," encompassing innovative pharmaceuticals (new drugs), established pharmaceuticals (generics), vaccines, and OTC products, which will globally respond to market and customer diversity and optimize growth opportunities across the value chain.
For more information, please visit: http://www.daiichisankyo.com or http://www.daiichi-sankyo.eu
Forward-looking statements
This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO, Co. Ltd, DAIICHI SANKYO, Inc., and DAIICHI SANKYO EUROPE GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO, Co. Ltd, DAIICHI SANKYO, Inc., and DAIICHI SANKYO EUROPE GmbH assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.
1. Cohen AT, Agnelli G, Anderson FA et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost 2007; 98:756-64.
2. Ruppert A et al. Economic burden of venous thromboembolism: a systematic review. Journal of Medical Economics Vol. 14, No. 1, 2011: 65-74.
3. PREFER in AF Observational Plan - Daiichi Sankyo data on file. August 2011
4. Clinicaltrials.gov: NCT00781391. Global Study to Assess the Safety and Effectiveness of DU-176b vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48) [Last accessed May 2012]. Available at: http://clinicaltrials.gov/ct2/show/NCT00...
5. Clinicaltrials.gov: NCT00986154. Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots.(The Edoxaban Hokusai- VTE Study).[Last accessed: July 2012]. Available at: http://www.clinicaltrials.gov/ct2/show/N...
6. Loue and Sajatovic Encyclopedia of Aging and Public Health 2008, XXIII, 843 p. 10 illus.
7. The Coalition to Prevent VTE. Available at: http://www.coalitiontopreventvte.org/ [http://www.coalitiontopreventvte.org ] . Accessed January 2013
8. Lung Disorders 2007 By Peter B. Terry, M.D.
9. Cleveland Clinic. Venous Thromboembolism. Available at: http://www.clevelandclinicmeded.com/medi... oembolism/ [http://www.clevelandclinicmeded.com/medi... ] . Accessed April 2012
10. NHS Choices. Atrial Fibrillation. Available at http://www.nhs.uk/conditions/Atrial-fibrillation/Pages/Intro.... Last accessed January 2013
11. Patient.co.uk http://www.patient.co.uk/pdf/pilsL10.pdf.... Last accessed January 2013
CONTACT: For more information, please contact: Daria Munsel, DaiichiSankyo Europe GmbH, +49(89)7808728 (Office)
